Prediction model for prognosis and monitoring curative effect of small cell lung cancer and construction method thereof

The ploid state of circulating tumor cells was identified through SE-iFISH technology and ACS scores were generated, which solved the problem of ignoring the ploid state in the prior art, and improved the accuracy of small-cell lung cancer prognosis and efficacy monitoring.

CN118919071APending Publication Date: 2024-11-08THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410926557.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-11
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing small-cell lung cancer prognosis and monitoring efficacy prediction techniques ignore the different ploidy states of circulating tumor cells, resulting in distortion of the model and low accuracy.

Method used

Differential phase enrichment-immunofluorescent chromosomal fluorescence in situ hybridization technology (SE-iFISH) was used to identify the triploid, tetraploid and polyploid status of circulating tumor cells, and the index was screened through single-factor and multi-factor Cox analysis. Circulating tumor cell ploid score (ACS) was generated, and patients were evaluated through ACS scores and their disease status was dynamically monitored.

Benefits of technology

It improves the accuracy of small cell lung cancer prognosis and monitoring efficacy prediction, and can more accurately evaluate the patient's prognosis and response to chemotherapy and immunotherapy effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118919071A_ABST
    Figure CN118919071A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biology, and particularly discloses a small cell lung cancer prognosis and curative effect monitoring prediction model and a construction method thereof.After the states of different ploids (triploid, tetraploid and polyploid) in circulating tumor cells are obtained through an SE-iFISH technology, indexes capable of being used for predicting prognosis are screened through single-factor and multi-factor Cox analysis; a correlation coefficient of each prediction index is obtained, and a circulating tumor cell ploid score (ACS) is generated for each patient; the ACS can be used for evaluating the prognosis condition of the small cell lung cancer patient, dynamically monitoring the disease state of the small cell lung cancer patient, and predicting the response of the patient to chemotherapy and immunotherapy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biotechnology, and in particular to a prediction model for the prognosis and monitoring efficacy of small cell lung cancer and a method for constructing the same. Background Art

[0002] Small cell lung cancer (SCLC) accounts for about 15% of all lung cancers and is characterized by rapid growth, early metastasis, and poor prognosis. Despite active treatment in the clinic, most patients eventually progress or relapse due to acquired drug resistance.

[0003] Currently, the prognosis of patients with small cell lung cancer can be evaluated early by monitoring the changes in peripheral blood circulating tumor cells (CTCs), and the response of patients with small cell lung cancer to treatment can be dynamically monitored. The current mainstream prediction technology is the CellSearch system, which enriches CTCs based on epithelial cell adhesion molecules (EpCAM) and identifies CTCs through cytokeratin (CK). However, this method not only ignores CTCs with mesenchymal phenotypes, but also fails to characterize the aneuploidy state of CTCs. Currently, differential phase enrichment-immunofluorescence staining-chromosome fluorescence in situ hybridization technology (SE-iFISH) is also used to enrich and identify the ploidy state of CTCs, but in clinical research and application, most researchers regard all circulating tumor cells as a whole to predict prognosis and monitor treatment effects; this method ignores the heterogeneity of different ploidies in circulating tumor cells, and the constructed model may be distorted, making the accuracy of the model for predicting prognosis and monitoring treatment low. Summary of the invention

[0004] The purpose of this application is to overcome the deficiencies of the above-mentioned prior art and provide a prediction model for the prognosis and monitoring of the efficacy of small cell lung cancer and a method for constructing it. This application uses different weights of different circulating tumor cells (triploid, tetraploid, polyploid) to finally obtain a circulating tumor cell ploidy score ACS, which can be used to evaluate the prognosis of patients with small cell lung cancer, and dynamically monitor the state of the disease in patients with small cell lung cancer, and can also predict the patient's response to chemotherapy and immunotherapy. The present invention solves the problem of real-time monitoring of treatment effects / prognosis evaluation, and better achieves precision treatment.

[0005] To achieve the above purpose, the technical solution adopted by this application is:

[0006] The present application provides a method for constructing a prediction model for the prognosis and monitoring efficacy of small cell lung cancer, comprising the following steps:

[0007] Differential phase enrichment-immunofluorescence staining combined with chromosome fluorescence in situ hybridization was used to obtain the different ploidy states in circulating tumor cells. Univariate and multivariate Cox analysis was performed to screen out indicators for predicting the prognosis of small cell lung cancer and monitoring the efficacy. The correlation coefficient of each indicator was obtained to generate a circulating tumor cell ploidy score ACS.

[0008] The circulating tumor cell ploidy score (ACS) was the weighted sum of each index and the Cox regression coefficient: ACS = 0.223*triploid number+0.444*tetraploid number+1.496*polyploid number; high-risk and low-risk patients were divided according to ACS.

[0009] In the technical solution of the present application, after using SE-iFISH technology to obtain the status of different ploidies (triploid, tetraploid, polyploid) in circulating tumor cells, univariate and multivariate Cox analysis is used to screen indicators that can be used to predict prognosis, and the correlation coefficient of each predictive indicator is obtained to generate a circulating tumor cell ploidy score (ACS) for each patient. The ACS is the weighted sum of each predictive indicator and the Cox regression coefficient: ACS = 0.223*number of triploids + 0.444*number of tetraploids + 1.496*number of polyploids; the above-mentioned ACS score can be used to evaluate the prognosis of patients with small cell lung cancer, dynamically monitor the disease status of patients with small cell lung cancer, and predict the patient's response to chemotherapy and immunotherapy.

[0010] The circulating tumor cell ploidy score ACS used in this application fully considers the contribution of different ploidies in the biological functions of tumors, making the model for predicting prognosis and monitoring treatment more accurate.

[0011] As a preferred embodiment of the method for constructing the prediction model described in the present application, immunofluorescence staining combined with chromosome fluorescence in situ hybridization is used to identify the number of triploid, tetraploid and polyploid circulating tumor cells.

[0012] As a preferred embodiment of the method for constructing the prediction model described in the present application, the circulating tumor cells are derived from peripheral blood.

[0013] Wherein, circulating tumor cells are enriched by differential phase enrichment, which specifically includes the following steps:

[0014] 1) Dilute the peripheral blood sample with 5 ml of phosphate buffer, centrifuge at 600 g for 5 minutes, and discard the plasma;

[0015] 2) Add 5 ml of red blood cell lysis buffer to the remaining precipitate, place the centrifuge tube in a vertical mixer and mix well, incubate at room temperature for 10 minutes (20 rpm), centrifuge at 400 g for 5 minutes, and discard the supernatant;

[0016] 3) Add 150 μl of CD45 antibody-coated immunomagnetic beads to the above precipitate and shake the centrifuge tube to mix thoroughly. Adjust the horizontal shaker to 100 rpm, fix the centrifuge tube on the shaker at a 40° angle, and shake at room temperature for 20 minutes;

[0017] 4) Place the centrifuge tube on a magnetic stand for 5 minutes, transfer the suspension to a 1.5 mL centrifuge tube, centrifuge at 2070 g for 3 minutes, and discard the supernatant to about 100 ul;

[0018] 5) Add 100 μl of 10% neutral formalin fixative, pipette and mix thoroughly for more than 10 times, and smear the sample (about 2 cm in diameter) onto an anti-shedding slide;

[0019] 6) Dry naturally.

[0020] The present application uses immunofluorescence staining-chromosome fluorescence in situ hybridization to identify the number of triploids, tetraploids and polyploids in circulating tumor cells, specifically including the following steps:

[0021] 1) Denature the slide containing circulating tumor cells in 70% formamide denaturing solution at 75°C for 5 minutes;

[0022] 2) Immediately dehydrate the specimens in order with a series of 70%, 90% and 100% ethanol by volume for 5 minutes each time, air dry at room temperature, and then operate in a dark place;

[0023] 3) Drop 10 μl of CEP 8 SpectrumGreen probe on the glass slide, cover with a coverslip, be careful to avoid bubbles, and seal the edge of the coverslip with paraffin sealing film;

[0024] 4) Place the slide on a Statspin ThermoBrite instrument for hybridization, and set the program: denaturation at 76°C for 5 minutes, hybridization at 37°C for 1.5 hours;

[0025] 5) Take out the slide, carefully tear off the sealing film, be careful not to move the cover glass, put the slide into 43℃ 50% formamide working solution, carefully shake off the cover glass, and wash with gentle shaking for 5 minutes. Repeat three times;

[0026] 6) Wash the sample area twice with 0.2% BSA, add 200 μl of Alexa Fluor 594-labeled monoclonal anti-CD45 antibody working solution, and incubate at room temperature in the dark for 1.5 hours;

[0027] 7) Wash the specimen area twice with 0.2% BSA and remove any remaining liquid;

[0028] 8) Finally, add 10 μl of mounting medium containing 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI) and cover the slide;

[0029] 9) Observe under Axio Imager Z2 fluorescence microscope at 40x objective magnification: triploids were DAPI+, CD45- and CEP8=3, tetraploids were DAPI+, CD45- and CEP8=4, and polyploids were DAPI+, CD45- and CEP8≥5.

[0030] 10) Count the number of triploid, tetraploid and polyploid circulating tumor cells in 5 ml of peripheral blood of each patient.

[0031] As a preferred embodiment of the method for constructing the prediction model described in the present application, the triploid is DAPI+, CD45- and CEP=3, the tetraploid is DAPI+, CD45- and CEP8=4, and the polyploid is DAPI+, CD45- and CEP8≥5.

[0032] As a preferred implementation of the method for constructing the prediction model described in the present application, the different ploidies in the obtained circulating tumor cells are included in the Cox proportional hazard model for univariate analysis to analyze the impact of single factors on survival time, and the factors that meet P < 0.1 in the univariate analysis are included in the multivariate analysis.

[0033] As a preferred implementation of the method for constructing the prediction model described in the present application, the multivariate analysis uses the Cox proportional hazard model to analyze the effects of two or more factors on survival time, and obtains independent prognostic factors with P<0.05. Triploidy, tetraploidy and polyploidy are all independent prognostic factors.

[0034] As a preferred embodiment of the method for constructing the prediction model described in the present application, the cutoff value of the circulating tumor cell ploidy score ACS is 1.115, and those with ACS values ​​greater than or equal to 1.115 are classified as a high-risk group, and those with ACS values ​​less than 1.115 are classified as a low-risk group.

[0035] The present application divides patients into a high-risk group (ACS ≥ 1.115) and a low-risk group (ACS < 1.115) by a specific ACS cutoff value.

[0036] The progression-free survival rate of patients in the high-risk group was lower than that in the low-risk ACS group, with a hazard ratio (HR) of 2.89 and a confidence interval (CI) of 1.68 to 4.98 at 95% confidence level, P<0.001; the overall survival rate of patients in the high-risk group was lower than that in the low-risk group, with a hazard ratio (HR) of 7.96 and a confidence interval (CI) of 4.03 to 15.70 at 95% confidence level, P<0.001.

[0037] As a preferred implementation of the method for constructing the prediction model described in the present application, the survfit() function in the survival package in the R language is used to analyze the progression-free survival rate and overall survival rate of the patient's ACS risk status.

[0038] As a preferred embodiment of the method for constructing the prediction model described in the present application, the circulating tumor cell ploidy score ACS is used for any of the following aspects:

[0039] 1) Predict the prognosis of small cell lung cancer;

[0040] 2) Dynamic monitoring of disease status;

[0041] 3) Predicting the efficacy of chemotherapy;

[0042] 4) Guide immunotherapy.

[0043] This application detected circulating tumor cells in the peripheral blood of patients before treatment (T0), during treatment and after treatment (T1, T2) and during follow-up, and analyzed the ACS status at different time points. Compared with before treatment, the ACS score of PD patients increased (P<0.001), the ACS of PR patients decreased compared with before treatment (P=0.036), and there was no significant change in the ACS score in the SD patient group. In addition, ACS is more sensitive than CT scan for follow-up PD assessment, with a median lead time of 2.8 months (IQR, 1.8-5.9 months).

[0044] This application analyzes the relationship between the status of peripheral blood circulating tumor cell scores before treatment and the chemotherapy effect in patients who only received chemotherapy. 46.6% (27 / 58) of patients with low ACS achieved objective remission (ORR) before treatment, while only 4.3% (1 / 23) of patients with high ACS achieved objective remission (P=0.001).

[0045] The present application also evaluates the ability of ACS to predict the response of patients to chemotherapy or chemotherapy combined with immunotherapy. When patients are at high risk for ACS before treatment, patients who use chemotherapy combined with immunotherapy have longer PFS (median PFS, 7.7 months; HR = 0.34 (95% CI, 0.15-0.74), P = 0.007) and OS (median OS, 16.3 months; HR = 0.44 (95% CI, 0.20-0.94), P = 0.033) than those who use chemotherapy alone.

[0046] The present application adopts the above-mentioned construction method to prepare a prediction model for the prognosis and monitoring of the therapeutic effect of small cell lung cancer, wherein the prediction model uses the number of triploids, tetraploids and polyploids as input variables.

[0047] Compared with the prior art, this application has the following beneficial effects:

[0048] The present application provides a prediction model for the prognosis and monitoring of the therapeutic effect of small cell lung cancer and a method for constructing the same. After obtaining the status of different ploidies (triploid, tetraploid, and polyploid) in circulating tumor cells using SE-iFISH technology, univariate and multivariate Cox analysis is used to screen indicators that can be used to predict prognosis, and the correlation coefficient of each prediction indicator is obtained to generate a circulating tumor cell ploidy score (ACS) for each patient. The ACS is a weighted sum of each prediction indicator and the Cox regression coefficient: ACS = 0.223*triploid number+0.444*tetraploid number+1.496*polyploid number; ACS can be used to evaluate the prognosis of patients with small cell lung cancer, dynamically monitor the disease status of patients with small cell lung cancer, and predict the patient's response to chemotherapy and immunotherapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] Figure 1 A flow chart of the method for constructing a prediction model for the prognosis and monitoring therapeutic effect of small cell lung cancer provided in Example 1;

[0050] Figure 2 Representative images of different types of ploidy CTCs (A is a triploid CTC; B is a tetraploid CTC; C is a polyploid CTC (yellow arrow) and leukocytes (white arrow));

[0051] Figure 3 The univariate and multivariate analysis diagrams of different ploidy of CTC in the training group as predictive variables for overall survival (OS) of patients with small cell lung cancer;

[0052] Figure 4 is the progression-free survival rate of high-risk ACS and low-risk ACS patients in the training group ( Figure 4 -A) Comparison with overall survival rate ( Figure 4 -B);

[0053] Figure 5 To verify the progression-free survival of high-risk ACS and low-risk ACS patients in the Figure 5 -A) Comparison with overall survival rate ( Figure 5 -B);

[0054] Figure 6 The relationship between the disease status and ACS changes before and after treatment ( Figure 6 -A) Comparison of the time between ACS and CT in monitoring disease progression ( Figure 6 -B);

[0055] Figure 7 Progression-free survival (PFS) with chemotherapy or chemotherapy plus immunotherapy for high-risk ACS patients Figure 7 -A) Comparison with overall survival rate ( Figure 7 -B). DETAILED DESCRIPTION

[0056] In order to better illustrate the purpose, technical solutions and advantages of the present application, the present application will be further described below in conjunction with the accompanying drawings and specific embodiments.

[0057] In the following examples, the experimental methods used are conventional methods unless otherwise specified, and the materials, reagents, etc. used are all commercially available unless otherwise specified.

[0058] Example 1: A method for constructing a prediction model for the prognosis and therapeutic efficacy of small cell lung cancer This embodiment provides a method for constructing a prediction model for the prognosis and monitoring efficacy of small cell lung cancer (process as shown in Figure 1 As shown), comprising the following steps:

[0059] Step 1: Screening and collecting patients with small cell lung cancer:

[0060] 1.1 Calculation of required sample size: Based on the log-rank test of equality of survival curves (implemented by PASS software), assuming a type I error of 0.05 and a type II error of 0.20, the 12-month survival probabilities for low-ACS and high-ACS patients were 0.6 and 0.3, respectively.

[0061] The specific operations are as follows:

[0062] 1) Start PASS software, select "Survival" in the "Category" on the left, click the "+" in front of it, expand it and select "Two Survival Curves";

[0063] 2) Select "Logrank Tests" in the program selection window on the right, and the system will open the parameter input window;

[0064] 3) In "Power and Alpha", type "0.80" for "Power" and "0.05" for "Alpha"; in "Sample Size", set "Group Allocation" to "Equal (N1 = N2)"; in "Effect Size", select "Proportion Surviving" for "Input Type", type "0.3" for "S1 (Proportion Surviving-Control)" (i.e., control group); select "S2 (Proportion Surviving-Treatment)" for "Treatment Group Parameter", type "0.60" for "S2 (Proportion Surviving Treatment)", and select "1" for "T0 (Survival Time)"; in "Duration", type "1" for "Accrual Time (integers Only)" and select "Uniform or For Equal, type "2" in "Total Time (Integers Only)".

[0065] 4) The sample size for calculating the primary endpoint survival rate was initially 88. As the proportion of patients in each group could not be determined, the sample size was expanded as much as possible to ensure that the final sample size could meet the needs of the study, and a total of 126 cases that met the inclusion and exclusion criteria were included.

[0066] 1.2 Enrollment conditions:

[0067] 1) Tumor classification: small cell lung cancer confirmed by histology or cytology;

[0068] 2) It was assessed that surgical resection was not possible;

[0069] 3) Patients aged between 18 and 80 years at the time of diagnosis;

[0070] 4) Physical activity status score (PS) ≤ 2 points;

[0071] 5) There is sufficient clinical information (meeting the basic requirements of the clinical information collection form) and good follow-up conditions.

[0072] 1.3 Exclusions:

[0073] 1) The patient has a history of other malignant tumors or has received other systemic treatments before diagnosis;

[0074] 2) The patient refuses to be examined;

[0075] 3) Clinical data is missing or not recorded in a standardized manner;

[0076] 4) The researcher judged that the patient was not suitable for participating in this study.

[0077] Step 2: Collect 5 ml of peripheral blood specimens from patients with small cell lung cancer in step 1 before treatment (T0), during treatment and after treatment (T1, T2) and during follow-up, and enrich circulating tumor cells using differential phase enrichment method; the specific steps include the following:

[0078] 1) Dilute the peripheral blood sample with 5 ml of phosphate buffer (Sigma #P-5368), centrifuge at 600 g for 5 minutes, and discard the plasma;

[0079] 2) Add 5 ml of red blood cell lysis buffer (Beyotime#C3702) to the remaining precipitate, place the centrifuge tube in a vertical mixer and mix well, incubate at room temperature for 10 minutes (20 rpm), centrifuge at 400 g for 5 minutes, and discard the supernatant;

[0080] 3) Add 150 μl of CD45 antibody-coated immunomagnetic beads (Cyttel #YYZH01) to the above precipitate and shake the centrifuge tube to mix thoroughly. Adjust the horizontal shaker to 100 rpm, fix the centrifuge tube on the shaker at a 40° angle, and shake at room temperature for 20 minutes;

[0081] 4) Place the centrifuge tube on a magnetic stand for 5 minutes, transfer the suspension to a 1.5 mL centrifuge tube, centrifuge at 2070 g for 3 minutes, and discard the supernatant to about 100 μl;

[0082] 5) Add 100 μl of 10% neutral formalin fixative (Biosharp#BL388A), mix thoroughly by pipetting for more than 10 times, and smear the sample (about 2 cm in diameter) onto an anti-shedding slide;

[0083] 6) Dry naturally.

[0084] Step 3: Use immunofluorescence staining-chromosome fluorescence in situ hybridization to identify the number of triploid, tetraploid and polyploid circulating tumor cells in step 1:

[0085] 1) Denature the slide containing circulating tumor cells in 70% formamide denaturing solution at 75°C for 5 minutes;

[0086] 2) Immediately dehydrate the specimens in order with a series of 70%, 90% and 100% ethanol by volume for 5 minutes each time, air dry at room temperature, and then operate in a dark place;

[0087] 3) Drop 10 μl CEP 8 Spectrum Green probe (Abbott #06J3718) on the glass slide, cover with a coverslip, be careful to avoid bubbles, and seal the edge of the coverslip with paraffin sealing film;

[0088] 3) Place the slide on the Statspin ThermoBrite instrument for hybridization, and set the program: denaturation at 76°C for 5 minutes and hybridization at 37°C for 1.5 hours;

[0089] 5) Take out the slide, carefully tear off the sealing film, be careful not to move the cover glass, put the slide into 43℃ 50% formamide working solution, carefully shake off the cover glass, and wash with gentle shaking for 5 minutes. Repeat three times;

[0090] 6) Wash the sample area twice with 0.2% BSA, add 200 μl of Alexa Fluor 594-labeled monoclonal anti-CD45 antibody working solution (CST#35154), and incubate at room temperature in the dark for 1.5 hours;

[0091] 7) Wash the specimen area twice with 0.2% BSA and remove any remaining liquid;

[0092] 8) Finally, add 10 μl of mounting medium containing DAPI (CST#8961) and cover the slide;

[0093] 9) Observe under Axio Imager Z2 fluorescence microscope at 40x objective magnification: triploids are DAPI+, CD45- and CEP8=3, tetraploids are DAPI+, CD45- and CEP8=4, and polyploids are DAPI+, CD45- and CEP8≥5. Figure 2 shown.

[0094] 10) Count the number of triploid, tetraploid and polyploid circulating tumor cells in 5 ml of peripheral blood of each patient.

[0095] Step 4: Establish a prognosis prediction model based on the circulating tumor cell ploidy information obtained in step 3:

[0096] 4.1 In order to obtain the most appropriate cutoff value for risk stratification, 126 patients were randomly assigned to the training group and the validation group;

[0097] 4.2Use the coxph() function in the survival package in R language to perform univariate and multivariate analysis (e.g. Figure 3 shown):

[0098] 1) Univariate analysis: The triploid, tetraploid, and polyploid in the peripheral blood circulating tumor cells obtained by the above method before the patient's treatment were included in the Cox proportional hazard regression model for univariate analysis to analyze the impact of univariate factors on survival time (overall survival). The HR of triploid was 1.118, P = 0.039; the HR of tetraploid was 2.110, P < 0.001; the HR of polyploid was 6.065, P < 0.001. Triploid, tetraploid, and polyploid all met P < 0.1 in the univariate analysis and were included in the multivariate analysis;

[0099] 2) Multivariate analysis: The triploid, tetraploid and polyploid in step 1 were included in the Cox proportional hazard regression model for multivariate analysis. The HR of triploid was 1.249, P = 0.024, and the correlation coefficient (coef) was 0.223; the HR of tetraploid was 1.559, P = 0.037, and the correlation coefficient was 0.444; the HR of polyploid was 4.464, P < 0.001, and the correlation coefficient was 1.496. Triploid, tetraploid and polyploid met P < 0.0.5 in the multivariate analysis, which means that these indicators can be used as independent prognostic factors (triploid, tetraploid and polyploid are all independent prognostic factors) and can be included in the establishment of the ACS model;

[0100] 4.3ACS is obtained by weighted summation of each prediction index and Cox regression coefficient: ACS = 0.223*triploid number+0.444*tetraploid number+1.496*polyploid number;

[0101] 4.4 Use the surv_cutpoint() function in the survminer package in R language to calculate the cutoff value of ACS as 1.115, and divide patients into high-risk and low-risk groups: patients with ACS values ​​greater than or equal to 1.115 are classified as high-risk group, and patients with ACS values ​​less than 1.115 are classified as low-risk group; or patients with ACS values ​​greater than or equal to 1.115 are classified as high ACS, and patients with ACS values ​​less than 1.115 are classified as low ACS;

[0102] according to Figure 4 The progression-free survival (PFS) of patients in the high-risk ACS group was lower than that in the low-risk ACS group ( Figure 4 -A), the hazard ratio (HR) was 2.89, and the confidence interval (CI) was 1.68 to 4.98 at 95% confidence level, P < 0.001; the overall survival (OS) of patients in the high-risk ACS group was lower than that in the low-risk ACS group ( Figure 4 -B), the hazard ratio (HR) was 7.96, and the confidence interval (CI) was 4.03 to 15.70 at 95% confidence level, P < 0.001.

[0103] 4.5 Verify in the verification group:

[0104] 1) According to the above definition, the patients in the validation group were divided into high-risk and low-risk groups for ACS;

[0105] 2) According to Figure 5 In the validation group, the progression-free survival (PFS) of patients in the high-risk ACS group was lower than that in the low-risk ACS group ( Figure 5 -A), the hazard ratio (HR) was 4.70, and the confidence interval (CI) was 2.19 to 10.08 at 95% confidence level, P < 0.001; the overall survival (OS) of patients in the high-risk ACS group was lower than that in the low-risk ACS group ( Figure 5 -B), the hazard ratio (HR) was 6.88, and the confidence interval (CI) was 3.11 to 15.26 at 95% confidence level, P < 0.001.

[0106] Step 5: Dynamically monitor the changes in ACS values ​​before, during, and after treatment and during follow-up, and evaluate the ability of ACS to predict disease status (CR, PR, SD, PD) based on imaging results;

[0107] 5.1 Detect circulating tumor cells in the peripheral blood of patients before treatment (T0), during treatment and after treatment (T1, T2) and during follow-up, and analyze the ACS status at different time points using the above model to compare the changes in ACS before and after treatment;

[0108] 5.2 Collect imaging data on disease monitoring before (T0), during and after treatment (T1, T2):

[0109] 1) Complete remission (CR) means that all tumor target lesions disappear without the appearance of new lesions, which lasts for 4 weeks;

[0110] 2) Partial response (PR) means that the sum of the maximum diameters of target tumor lesions is reduced by ≥30% and maintained for at least 4 weeks;

[0111] 3) Stable lesion (SD) means that the sum of the maximum diameters of the target tumor lesions has not decreased to PR, or has not increased to PD;

[0112] 4) Progressive disease (PD) refers to an increase of at least 20% in the sum of the maximum diameters of target tumor lesions or the appearance of new lesions.

[0113] 5.3 Compare the relationship between ACS change trends and imaging assessment of disease progression.

[0114] Circulating tumor cells were detected in the peripheral blood of patients before treatment (T0), during treatment and after treatment (T1, T2) and during follow-up, and the ACS status at different time points was analyzed using the above model.

[0115] The results are as follows Figure 6As shown in the figure, compared with before treatment, the ACS score of PD patients increased (P<0.001), the ACS score of PR patients decreased compared with before treatment (P=0.036), and there was no significant change in the ACS score in the SD patient group ( Figure 6 In addition, ACS was more sensitive than CT scan for follow-up PD assessment, with a median lead time of 2.8 months (IQR, 1.8-5.9 months, Figure 6 -B).

[0116] Step 6: Evaluation of chemotherapy effects in high- and low-risk groups for ACS before treatment:

[0117] 6.1 Screen patients who received chemotherapy only (81 of the 126 patients mentioned above were screened) and divide patients into high-risk and low-risk groups according to their pre-treatment ACS;

[0118] 6.2 Objective response rate (ORR): The proportion of patients whose tumor volume shrinks to the pre-specified value and can maintain the minimum required time limit (CR+PR);

[0119] 6.3 Disease control rate (DCR): the proportion of patients whose tumors achieve remission (PR+CR) and stable lesions (SD) after treatment and can maintain the minimum time limit;

[0120] 6.4 Compare the ORR and DCR of high-risk and low-risk groups after chemotherapy.

[0121] The relationship between the status of peripheral blood circulating tumor cell scores before treatment and the chemotherapy effect in patients who received only chemotherapy was analyzed. 46.6% (27 / 58) of patients with low ACS before treatment achieved objective remission (ORR), while only 4.3% (1 / 23) of patients with high ACS achieved objective remission (P=0.001, Table 1).

[0122] Table 1 Treatment response of patients stratified by ACS in chemotherapy subgroups (data are expressed in n%)

[0123]

[0124] Step 7: Evaluate the effect of chemotherapy combined with immunotherapy in high- and low-risk groups for ACS before treatment.

[0125] 7.1 Screening of patients receiving chemotherapy and chemotherapy combined with immunotherapy (screening of 116 of the above 126 cases; chemotherapy drugs were etoposide / carboplatin or etoposide / cisplatin, and immunotherapy drugs were durvalumab, atezolizumab, nivolumab, or pembrolizumab). Patients were divided into high-risk and low-risk groups according to their ACS before treatment; the results were as follows Figure 7As shown in the results, when patients were at high risk of ACS before treatment, patients who used chemotherapy combined with immunotherapy had a longer PFS than those who used chemotherapy alone (median PFS, 7.7 months; HR = 0.34 (95% CI, 0.15-0.74), P = 0.007; Figure 7 -A) and OS (median OS, 16.3 months; HR = 0.44 (95% CI, 0.20-0.94), P = 0.033; Figure 7 -B).

[0126] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present application rather than to limit the scope of protection of the present application. Although the present application has been described in detail with reference to the preferred embodiments, ordinary technicians in this field should understand that the technical solution of the present application can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present application.

Claims

1. A method for constructing a prediction model for the prognosis and monitoring therapeutic effect of small cell lung cancer, characterized in that: The following steps are involved: Differential phase enrichment-immunofluorescence staining combined with chromosome fluorescence in situ hybridization was used to obtain the different ploidy states in circulating tumor cells. Univariate and multivariate Cox analysis was performed to screen out indicators for predicting the prognosis of small cell lung cancer and monitoring the efficacy. The correlation coefficient of each indicator was obtained to generate a circulating tumor cell ploidy score ACS. The circulating tumor cell ploidy score (ACS) was the weighted sum of each index and the Cox regression coefficient: ACS = 0.223*triploid number+0.444*tetraploid number+1.496*polyploid number; high-risk and low-risk patients were divided according to ACS.

2. The method for constructing a prediction model according to claim 1, wherein: Immunofluorescence staining combined with chromosome fluorescence in situ hybridization was used to identify the number of triploid, tetraploid and polyploid circulating tumor cells.

3. The method for constructing a prediction model according to claim 1, wherein: The circulating tumor cells are derived from peripheral blood.

4. The method for constructing a prediction model according to claim 1, wherein: The triploids were DAPI+, CD45-, and CEP=3, the tetraploids were DAPI+, CD45-, and CEP8=4, and the polyploids were DAPI+, CD45-, and CEP8≥5.

5. The method for constructing a prediction model according to claim 1, wherein: The different ploidy levels of circulating tumor cells were included in the Cox proportional hazard model for univariate analysis to analyze the effect of univariate factors on survival time, and the factors with P < 0.1 in the univariate analysis were included in the multivariate analysis.

6. The method for constructing a prediction model according to claim 1, wherein: The multivariate analysis used the Cox proportional hazard model to analyze the effects of two or more factors on survival time, and obtained independent prognostic factors with P<0.

05. Triploidy, tetraploidy and polyploidy were all independent prognostic factors.

7. The method for constructing a prediction model according to claim 1, wherein: The cutoff value of the circulating tumor cell ploidy score ACS is 1.115, and patients with an ACS value greater than or equal to 1.115 are classified as a high-risk group, and patients with an ACS value less than 1.115 are classified as a low-risk group.

8. The method for constructing a prediction model according to claim 1, wherein: The survfit() function in the survival package in R language was used to analyze the progression-free survival and overall survival of patients with ACS risk status.

9. The method for constructing a prediction model according to claim 1, wherein: ACS is used to score circulating tumor cells for any of the following: 1) Predict the prognosis of small cell lung cancer; 2) Dynamic monitoring of disease status; 3) Predicting the efficacy of chemotherapy; 4) Guide immunotherapy.

10. A prediction model for the prognosis and monitoring of therapeutic efficacy of small cell lung cancer prepared by the construction method according to any one of claims 1 to 9, wherein the prediction model uses the number of triploids, tetraploids and polyploids as input variables.